Immunome, Inc. (IMNM)
- Previous Close
15.15 - Open
14.93 - Bid 15.15 x 400
- Ask 15.23 x 400
- Day's Range
14.93 - 15.35 - 52 Week Range
4.76 - 30.96 - Volume
309,170 - Avg. Volume
756,300 - Market Cap (intraday)
911.527M - Beta (5Y Monthly) 1.85
- PE Ratio (TTM)
-- - EPS (TTM)
-17.58 - Earnings Date Aug 7, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
33.25
Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
immunome.comRecent News: IMNM
Performance Overview: IMNM
Trailing total returns as of 6/7/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IMNM
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IMNM
Valuation Measures
Market Cap
911.53M
Enterprise Value
603.45M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
23.22
Price/Book (mrq)
3.19
Enterprise Value/Revenue
47.58
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-15.16%
Return on Equity (ttm)
-154.98%
Revenue (ttm)
12.68M
Net Income Avi to Common (ttm)
-232.03M
Diluted EPS (ttm)
-17.58
Balance Sheet and Cash Flow
Total Cash (mrq)
309.71M
Total Debt/Equity (mrq)
0.57%
Levered Free Cash Flow (ttm)
-18.52M